CN106619532B - 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 - Google Patents
一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 Download PDFInfo
- Publication number
- CN106619532B CN106619532B CN201611021750.2A CN201611021750A CN106619532B CN 106619532 B CN106619532 B CN 106619532B CN 201611021750 A CN201611021750 A CN 201611021750A CN 106619532 B CN106619532 B CN 106619532B
- Authority
- CN
- China
- Prior art keywords
- roxithromycin
- essence
- ambroxol hydrochloride
- suspention
- fluidized bed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 title claims abstract description 98
- 229960005224 roxithromycin Drugs 0.000 title claims abstract description 98
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229960000985 ambroxol hydrochloride Drugs 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 38
- 239000000463 material Substances 0.000 claims abstract description 30
- 238000000576 coating method Methods 0.000 claims abstract description 29
- 239000011248 coating agent Substances 0.000 claims abstract description 24
- 238000004090 dissolution Methods 0.000 claims abstract description 23
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 10
- 239000000853 adhesive Substances 0.000 claims abstract description 9
- 230000001070 adhesive effect Effects 0.000 claims abstract description 9
- 239000003085 diluting agent Substances 0.000 claims abstract description 7
- 229930006000 Sucrose Natural products 0.000 claims description 20
- 239000005720 sucrose Substances 0.000 claims description 20
- -1 stearic acid sucrose ester Chemical class 0.000 claims description 17
- 239000002994 raw material Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000230 xanthan gum Substances 0.000 claims description 11
- 235000010493 xanthan gum Nutrition 0.000 claims description 11
- 229920001285 xanthan gum Polymers 0.000 claims description 11
- 229940082509 xanthan gum Drugs 0.000 claims description 11
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 230000003750 conditioning effect Effects 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 238000005469 granulation Methods 0.000 claims description 8
- 230000003179 granulation Effects 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
- 229920003081 Povidone K 30 Polymers 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 235000009434 Actinidia chinensis Nutrition 0.000 claims description 2
- 244000298697 Actinidia deliciosa Species 0.000 claims description 2
- 235000009436 Actinidia deliciosa Nutrition 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 244000241235 Citrullus lanatus Species 0.000 claims description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 17
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 10
- 239000000843 powder Substances 0.000 abstract description 10
- 239000000375 suspending agent Substances 0.000 abstract description 6
- 229960003276 erythromycin Drugs 0.000 abstract description 5
- 238000005243 fluidization Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000007921 spray Substances 0.000 abstract description 2
- 238000005507 spraying Methods 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract 1
- 239000000686 essence Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 235000019640 taste Nutrition 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 235000019658 bitter taste Nutrition 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 230000000873 masking effect Effects 0.000 description 6
- 229960005174 ambroxol Drugs 0.000 description 5
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 235000010981 methylcellulose Nutrition 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001507 sample dispersion Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- XBFISNPWDYRTRZ-UHFFFAOYSA-N N.Cl.[Br] Chemical compound N.Cl.[Br] XBFISNPWDYRTRZ-UHFFFAOYSA-N 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000025301 tympanitis Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种罗红霉素氨溴索干混悬剂及其制备方法,采用的粉末包衣法先将罗红霉素置流化床内,调节合适的风量,使之能充分流化;将包衣材料加热熔化,在压缩空气的作用下通过喷雾装置将熔化的包衣材料和乳化剂混合液均匀喷洒在流化的罗红霉素表面,形成罗红霉素包衣物,然后加入盐酸氨溴索、稀释剂、粘合剂,通过流化床顶喷制粒,干燥后加入助悬剂和矫味剂,混合均匀,即为干混悬剂。本发明掩盖了罗红红霉素的不良气味,且不影响药物体内吸收,并且具有较高的溶出度。
Description
技术领域
本发明属于药物制剂领域,具体地说涉及一种罗红霉素盐酸氨溴索干混悬剂及其制备方法。
背景技术
呼吸道感染、慢性支气管炎等疾病是比较常见的呼吸道疾病,经典疗法是联合用药,特别是对小儿(各生理功能未完善)和老人(各生理功能已退化),药物的联用将会提高抗生素的疗效。大环内酯类抗生素罗红霉素和祛痰药物盐酸氨溴索组成复方制剂,能有效治疗由敏感微生物引起的细菌性急性支气管炎、慢性支气管炎的急性加重、支气管肺炎、典型性病原体肺炎、合并细菌感染的支气管哮喘或支气管扩展、鼻窦炎和中耳炎等。印度Sarabhai Piramal公司将罗红霉素与盐酸氨溴索组合在一起,上市了复方片剂的产品,规格:150mg的罗红霉素,30mg的盐酸氨溴索。罗红霉素和盐酸氨溴索在临床应用较早,疗效明确,两药联用,有增效作用。
例如,中国专利申请CN1698040A公开了一种适于儿童服用的罗红霉素与盐酸氨溴索的复方散剂,是通过将罗红霉素和盐酸氨溴索与氧化镁、十二烷基硫酸钠、羟丙纤维素、黄原胶、香料、阿斯巴坦、蔗糖等药用辅料制成为颗粒剂形式的罗红霉素氨溴索散剂,但是该散剂在服用时需要大量的温开水溶解药物,不仅降低了药物浓度,导致药物的生物利用度降低,而且还造成服用困难。
中国专利申请CN1582954A公开了一种罗红霉素和盐酸氨溴索的复方制剂,其具体公开的制剂形式有胶囊和片剂,但这种普通胶囊和片剂形式的罗红霉素氨溴索,在口服后体内溶解较为缓慢,而且难以达到完全溶解,导致药物的生物利用度降低,不能取得理想的抗菌效果。
罗红霉素对酸稳定,是目前临床上使用广泛、疗效优良的新型红霉素产品。罗红霉素为白色或类白色的结晶性粉末;无臭,味苦,略有阴湿性。本品在乙醇或丙酮中易溶,在甲醇或乙醚中溶解,在水中几乎不溶。盐酸氨溴索为白色或类白色结晶性粉末;无臭,无味。但是,罗红霉素属于浓度依赖型抗生素,抗菌效果与药物的浓度密切相关,现有技术中存在的普通制剂常因崩解和溶出缓慢而影响药物的充分吸收,从而难以达到令人满意的治疗效果。
目前,口服罗红霉素氨溴索氨溴索制剂临床常用的剂型为片剂和胶囊剂,但对于婴幼儿、儿童及其他吞服有困难的患者来说,片剂和胶囊剂存在明显的弊端。又因为本品味道极苦,采用添加甜味剂和矫味剂等常规的掩味方法丝毫不能掩盖其苦味,因此市面上罗红霉素氨溴索氨溴索干混悬剂或颗粒剂普遍存在口感不佳的情况,严重影响患者服药的顺应性,因此针对干混悬剂的掩味技术一直是药学上的难题。对于罗红霉素的掩味技术,流化床加入惰性包衣材料制成干混悬剂,惊喜地发现本发明的干混悬剂药物混悬状况良好,溶出度提高,从而完成了本发明。
发明内容
本发明的目的是克服以上技术的不足,提供了一种罗红霉素氨溴索药物组合物及其制备方法,以改善罗红霉素制剂的口味,提高服用顺应性,并方便现代制药业工业化大生产。
为实现上述目的,本发明采用的技术方案是:
一种罗红霉素氨溴索干混悬剂,其特征在于由如下原辅料制成:
作为优选的,本发明所提供的组合物干混悬剂由如下原辅料制成:
作为优选的,所述包衣材料为硬脂酸、山嵛酸甘油酯和单硬脂酸甘油酯中的一种或几种的混合物;所述乳化剂为聚乙烯吡咯烷酮K30、硬脂酸蔗糖酯和棕榈酸蔗糖酯的一种或两种混合物。
作为优选的,所述稀释剂选自蔗糖、乳糖、葡萄糖、果糖、甘露醇、山梨醇、木糖醇和赤藓糖醇中的一种或几种的混合物,更优选蔗糖和甘露醇的混合物。
作为优选的,所述香精选自香蕉香精、桔子香精、柠檬香精、水蜜桃香精、奶油香精、巧克力香精、草莓香精、菠萝香精、苹果香精、猕猴桃香精、葡萄香精、西瓜香精、哈密瓜香精中的一种或几种的混合物。
本发明还提供例上述罗红霉素氨溴索干混悬剂的制备方法,其特征在于包括如下步骤:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为包衣材料和乳化剂作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、稀释剂混合均匀,以羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得干混悬剂。
相对于现有技术,本发明具有以下的有益效果:
(1)常用的掩味技术有添加矫味剂、固体分散体法、包合法、药物微球/微囊化法、离子交换法等。而罗红霉素具有味道极苦、服用剂量较大,对湿热不稳定等特点,因此上述的掩味方法并不适用。本发明采用粉末包衣法利用流化床技术将罗红霉素均匀分散在熔融的包衣材料中,采用流化床制粒来达到掩盖苦味的目的,同时加入乳化剂作为溶出调节剂,使掩味层具有水渗透性,利于药物的释放。采用粉末包衣法掩盖了罗红红霉素的不良气味,且不影响药物体内吸收,并且具有较高的溶出度。
(2)本发明采用的粉末包衣法属于薄膜包衣范畴,其是流化床技术,将药物粉末直接一步包衣,达到掩味或控制释放的目的,是目前固体制剂发展的新方向。制备时,先将罗红霉素置流化床内,调节合适的风量,使之能充分流化。将包衣材料加热熔化,在压缩空气的作用下通过喷雾装置将熔化的包衣材料和乳化剂混合液均匀喷洒在流化的罗红霉素表面,此时液体状态的包衣材料浸润在罗红霉素表面,遇冷凝固,包衣材料不断地凝固、镶嵌或融合,经过反复堆积,最终形成有内部孔道的完整的包衣层。将上述包衣的罗红霉素中加入稀释剂、粘合剂,通过流化床顶喷制粒,干燥后加入助悬剂和香精,混合均匀,即为干混悬剂。
具体实施方式
为了更好的理解本发明的内容,下面结合具体实施例来做进一步的说明,但具体的实施方式并不是对本发明的内容所做的限制。
实施例1:
一种罗红霉素氨溴索干混悬剂,由如下原辅料制成1000袋:
制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为硬脂酸和聚乙烯吡咯烷酮K30作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、蔗糖混合均匀,以2%羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得1000袋干混悬剂,2g/袋。
实施例2:
一种罗红霉素氨溴索干混悬剂,由如下原辅料制成1000袋:
制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为单硬脂酸甘油酯和硬脂酸蔗糖酯作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、乳糖混合均匀,以2%羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得1000袋干混悬剂,1.0g/袋。
实施例3:
一种罗红霉素氨溴索干混悬剂,由如下原辅料制成1000袋:
制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为山嵛酸甘油酯和棕榈酸蔗糖酯作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、山梨醇、蔗糖混合均匀,以2%羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得1000袋干混悬剂,1.5g/袋。
实施例4:
一种罗红霉素氨溴索干混悬剂,由如下原辅料制成1000袋:
制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为山嵛酸甘油酯、单硬脂酸甘油酯、硬脂酸蔗糖酯和棕榈酸蔗糖酯作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、甘露醇、蔗糖混合均匀,以2%羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得1000袋干混悬剂,1.8g/袋。
【试验例1】
1、苦味测试:
将实施例1-4制备得到的罗红霉素干混悬剂分别给予50名健康志愿受试者,让其服用后,记录受试者口感:样品一袋(含罗红霉素50mg、盐酸氨溴索10mg)分别分散在25℃水50ml中,10min后,每个志愿者依次对各个样品进行评价,口含lml样品分散液30s,然后吐出,评价苦味的等级。漱口,再按上述方法评价另外两种样品。一半或一半以上的志愿者选味苦或略苦则判定该样品味苦。结果见表1。
表1本发明干混悬剂的口感评价结果
从表1结果可以看出,实施例1-4的罗红霉素先进行包衣物制备,再进行流化床制备干混悬剂,与上市罗红霉素氨溴索干混悬剂相比,实施例1-4罗红霉素的苦味得到掩盖。
2、溶出度测定:
将实施例1-4的罗红霉素氨溴索干混悬剂样品,参照文献(孙峰,姚宏涛.比色法测定罗红霉素氨溴索干混悬剂的溶出度.中国药品标准.2009,10(3):225-228.)进行溶出度测定。
方法:取本品,照溶出度测定法(《中国药典))2010年版二部附录X C第二法),以盐酸溶液(1→1000)600mL为溶出介质,转速为75r/min,依法操作,30min时,取溶液适量,滤过,续滤液作为供试品溶液;另取装量差异项下的内容物,混合均匀,精密称取适量(约相当于罗红霉素50mg),加乙醇适量(每5mg罗红霉素加乙醇1mL)使罗红霉素溶解,用盐酸溶液(1→l 000)稀释成每l mL中含80μg的溶液,滤过,续滤液作为对照溶液;精密量取上述供试品溶液与对照溶液各5mL,分别精密加入硫酸溶液(75→100)5mL,摇匀,放置30min,冷却至室温,照紫外可见分光光度法(附录ⅣA),在482nm的波长处分别测定吸光度,计算每袋的溶出量。限度为80%。溶出度测定结果见表2。
表2本发明干混悬剂的溶出度测定结果
结果本发明的干混悬剂表现出良好的溶出行为,30min的溶出度均大于85%,说明在该范围内罗红霉素的苦味得到了良好的掩盖,并且其溶出度不受影响。
【试验例2】罗红霉素氨溴索干混悬剂的处方筛选试验
1、罗红霉素包衣物的处方优选
由于本制剂中盐酸氨溴索无苦味,故仅考虑罗红霉素的问题。按表1的处方分别在流化床中将罗红霉素制备成罗红霉素包衣物,分装,每袋含罗红霉素50mg。分别进行口味测试和溶出度测定。将制备得到的罗红霉素包衣物分别给予20名健康志愿受试者,让其服用后,记录受试者口感;样品一袋(含罗红霉素50mg)分别分散在25℃水50ml中,10min后,每个志愿者依次对各个样品进行评价,口含lml样品分散液30s,然后吐出,评价苦味的等级。漱口,再按上述方法评价另外两种样品。一半或一半以上的志愿者选味苦或略苦则判定该样品味苦。结果见表3。
罗红霉素包衣物制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为包衣材料和乳化剂作为溶出调节剂混合均匀,加热熔融;其中包衣材料为硬脂酸、山嵛酸甘油酯、单硬脂酸甘油酯的一种或一种以上;乳化剂为聚乙烯吡咯烷酮K30、棕榈酸蔗糖酯、硬脂酸蔗糖酯的一种或一种以上。
C)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物。
表3罗红霉素包衣物的处方优选结果
采用本发明制备的罗红霉素包衣物在罗红霉素:包衣材料:乳化剂的重量比为50:200~400:20~40的范围内表现出良好的溶出行为,30min的溶出度均大于85%,口感为苦味很淡或有苦味,可接受,说明在该范围内罗红霉素的苦味得到了良好的掩盖,并且其溶出度不受影响。
2、助悬剂的选择
由于本制剂中盐酸氨溴索溶于水,故仅考虑罗红霉素的助悬问题。常用助悬剂为:羧甲基纤维素钠、甲基纤维素、HPMC、黄原胶等,因罗红霉素分子结构中含有氨基,故不选择羧甲基纤维素钠,另外,甲基纤维素口感不好,故也不予考虑。本制剂只对HPMC、黄原胶进行筛选。
罗红霉素包衣物制备工艺:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料作为单硬脂酸甘油酯和硬脂酸蔗糖酯作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物。
E)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、蔗糖混合均匀,以羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得干混悬剂。
沉降体积比测定:取本品,置于具塞量筒中,加水50ml,密塞,用力振摇1分钟,记下混悬物的开始高度H0,静置3小时,记下混悬物的最终高度H,按下式计算:沉降体积比=H/H0(中国药典2000年版二部附录I O)。结果见表4。
表4助悬剂筛选结果
综合考虑,处方3-6最佳(沉降体积比值大,口感好),故选择黄原胶、HPMC作为助悬剂。
(三)处方工艺稳定性考察
采用上述表4处方6制备的样品经强光、高温(40℃、60℃)、高湿考察10天,(结果见表5)。本品在光照、40℃下稳定,在60℃和相对湿度75%放置10天,罗红霉素、氨溴索的有关物质有所增加,提示该产品应防潮,保存温度不宜过高。
表5影响因素试验结果
根据上述试验,确定本处方及工艺。
Claims (5)
1.一种罗红霉素盐酸氨溴索干混悬剂,其特征在于由如下原辅料制成:
所述包衣材料为硬脂酸、山嵛酸甘油酯和单硬脂酸甘油酯中的一种或几种的混合物;所述乳化剂为聚乙烯吡咯烷酮K30、硬脂酸蔗糖酯和棕榈酸蔗糖酯的一种或两种混合物;
所述罗红霉素盐酸氨溴索干混悬剂,其制备方法包括以下步骤:
a)原辅料分别粉碎过80目筛,备用;
b)取处方量的包衣材料和乳化剂作为溶出调节剂混合均匀,加热熔融;
c)在流化床内,调节合适的风量,使罗红霉素原料充分流化;
d)在流化床内,调节合适的温度,在压缩空气的作用下使难溶性材料形成雾化液滴,缓慢喷洒在充分流化的罗红霉素原料表面,使之均匀包被,得罗红霉素包衣物;
e)将步骤d)所得罗红霉素包衣物与盐酸氨溴索、黄原胶、稀释剂混合均匀,以羟丙甲纤维素溶液为粘合剂,流化床制粒,干燥,加香精,混合均匀,分装,即得干混悬剂。
2.如权利要求1所述的罗红霉素盐酸氨溴索干混悬剂,其特征在于由如下原辅料制成:
3.如权利要求1所述的罗红霉素盐酸氨溴索干混悬剂,其特征在于:稀释剂选自蔗糖、乳糖、葡萄糖、果糖、甘露醇、山梨醇、木糖醇和赤藓糖醇中的一种或几种的混合物。
4.如权利要求1所述的罗红霉素盐酸氨溴索干混悬剂,其特征在于:香精选自香蕉香精、桔子香精、柠檬香精、水蜜桃香精、奶油香精、巧克力香精、草莓香精、菠萝香精、苹果香精、猕猴桃香精、葡萄香精、西瓜香精、哈密瓜香精中的一种或几种的混合物。
5.如权利要求1所述的罗红霉素盐酸氨溴索干混悬剂,其特征在于:稀释剂为蔗糖和甘露醇的混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611021750.2A CN106619532B (zh) | 2016-11-16 | 2016-11-16 | 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611021750.2A CN106619532B (zh) | 2016-11-16 | 2016-11-16 | 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106619532A CN106619532A (zh) | 2017-05-10 |
CN106619532B true CN106619532B (zh) | 2019-09-06 |
Family
ID=58808192
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611021750.2A Active CN106619532B (zh) | 2016-11-16 | 2016-11-16 | 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106619532B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113181133A (zh) * | 2021-04-25 | 2021-07-30 | 海南通用三洋药业有限公司 | 一种罗红霉素胶囊的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857296A (zh) * | 2006-04-14 | 2006-11-08 | 北京润德康医药技术有限公司 | 一种以罗红霉素与盐酸氨溴索为活性成分的药用组合物及其制备方法、用途 |
CN101816672A (zh) * | 2010-03-27 | 2010-09-01 | 海南康芝药业股份有限公司 | 一种含有罗红霉素氨溴索的组合物及其制备方法 |
CN102125540A (zh) * | 2010-01-18 | 2011-07-20 | 沈阳华泰药物研究有限公司 | 含非盐形式的氨溴索药学上可接受的组合物 |
CN102286045A (zh) * | 2011-09-07 | 2011-12-21 | 山东罗欣药业股份有限公司 | 罗红霉素一水合物结晶、其制备方法及含该结晶和盐酸氨溴索组合的组合物干混悬剂 |
CN102358749A (zh) * | 2011-10-27 | 2012-02-22 | 山东罗欣药业股份有限公司 | 一种罗红霉素氨溴索片剂组合物及其制备方法 |
CN102526084A (zh) * | 2011-12-13 | 2012-07-04 | 海南康芝药业股份有限公司 | 一种罗红霉素氨溴索片 |
CN105560210A (zh) * | 2015-11-26 | 2016-05-11 | 陕西高新能源发展有限公司 | 罗红霉素干混悬剂及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070009564A1 (en) * | 2005-06-22 | 2007-01-11 | Mcclain James B | Drug/polymer composite materials and methods of making the same |
-
2016
- 2016-11-16 CN CN201611021750.2A patent/CN106619532B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1857296A (zh) * | 2006-04-14 | 2006-11-08 | 北京润德康医药技术有限公司 | 一种以罗红霉素与盐酸氨溴索为活性成分的药用组合物及其制备方法、用途 |
CN102125540A (zh) * | 2010-01-18 | 2011-07-20 | 沈阳华泰药物研究有限公司 | 含非盐形式的氨溴索药学上可接受的组合物 |
CN101816672A (zh) * | 2010-03-27 | 2010-09-01 | 海南康芝药业股份有限公司 | 一种含有罗红霉素氨溴索的组合物及其制备方法 |
CN102286045A (zh) * | 2011-09-07 | 2011-12-21 | 山东罗欣药业股份有限公司 | 罗红霉素一水合物结晶、其制备方法及含该结晶和盐酸氨溴索组合的组合物干混悬剂 |
CN102358749A (zh) * | 2011-10-27 | 2012-02-22 | 山东罗欣药业股份有限公司 | 一种罗红霉素氨溴索片剂组合物及其制备方法 |
CN102526084A (zh) * | 2011-12-13 | 2012-07-04 | 海南康芝药业股份有限公司 | 一种罗红霉素氨溴索片 |
CN105560210A (zh) * | 2015-11-26 | 2016-05-11 | 陕西高新能源发展有限公司 | 罗红霉素干混悬剂及其制备方法 |
Non-Patent Citations (2)
Title |
---|
"比色法测定罗红霉素氨溴索干混悬剂的溶出度";孙峰等;《中国药品标准》;20091231;第10卷(第3期);第225-228页 |
"罗红霉素包衣掩味制备干混悬剂处方和工艺";周青华等;《北方药学》;20151231;第12卷(第3期);第107-108页 |
Also Published As
Publication number | Publication date |
---|---|
CN106619532A (zh) | 2017-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2169376C (en) | Procedure for encapsulating nsaids | |
DE69934505T2 (de) | Im munde zerfallende tablette enthaltend ein benzimidazole | |
CN1886119B (zh) | 泮托拉唑多颗粒制剂 | |
CN113262208B (zh) | 一种阿奇霉素掩味的干混悬颗粒剂及其制备方法 | |
CN104274409A (zh) | 一种易于吞服的药物微球及其制备方法 | |
WO2022081814A1 (en) | Inhalable cannabinoid formulations | |
CN102727452B (zh) | 一种含右佐匹克隆的颗粒及其制备方法 | |
CN113041231B (zh) | 一种替比培南酯细粒剂组合物及其制备方法 | |
JP3221891B2 (ja) | 咀嚼可能な製薬錠剤調製のための回転造粒及び味覚遮蔽被覆加工 | |
CN106619532B (zh) | 一种罗红霉素盐酸氨溴索干混悬剂及其制备方法 | |
CN103054813A (zh) | 阿奇霉素口服缓释干混悬剂及其制备方法 | |
CN101020060A (zh) | 恩替卡韦的环糊精包合物及其制备方法和药物应用 | |
CN107613978B (zh) | Mek抑制剂的药物组合物及其制备方法 | |
CN105555257A (zh) | 微粉化的药物组合物 | |
CN107625733B (zh) | 一种克拉霉素无水吞服颗粒剂及其制备方法 | |
CN114209661B (zh) | 呈细粒形式的固体药物组合物 | |
CN110548008A (zh) | 阿考替胺固体分散体及其组合物 | |
CN104622825A (zh) | 一种阿奇霉素分散片 | |
CN103816123B (zh) | 一种头孢呋辛酯组合物及其制备方法 | |
CN102824331A (zh) | 扎来普隆双释放胶囊及其制备方法 | |
CN114699384A (zh) | 一种药物掩味方法、药物及其应用 | |
EP4035733A1 (en) | Granule having masked unpleasant taste and method for producing same | |
WO2022227116A1 (zh) | 一种罗红霉素胶囊的制备方法 | |
CN112972398A (zh) | 一种盐酸小檗碱颗粒剂及其制备方法 | |
CN114522166B (zh) | 一种固体分散体组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zonglin Inventor after: Wang Jun Inventor after: Gao Shuqing Inventor after: Liu Huaibin Inventor before: Wang Jun Inventor before: Gao Shuqing Inventor before: Liu Huaibin |
|
CB03 | Change of inventor or designer information |